Author

C. Lengerke

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Assay:organoid / primary culture· 1

Frequent Co-Authors

M. Klimiankou· 2 shared A. Dahmani· 1 shared A. N. Lupas· 1 shared B. Hernandez Alvarez· 1 shared C. Ercan· 1 shared C. K. Ng· 1 shared C. Pollmann· 1 shared E. Goersch· 1 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 17 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

M. Klimiankou

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Laminin Receptor Characterization in Acute Myeloid Leukemia: Integrin α7β1 Defines non-Leukemic Stem Cells with Migratory Potential

E. Goersch, M. Arnone, M. Klimiankou, J. Weller, S. Rudat, G. Klein, C. Lengerke

This study examines laminin receptors in AML, finding that integrin α7β1 marks non-leukemic stem cells with migratory potential and correlates with poor survival.

bioRxiv · Mar 29, 2024 · PreprintCancer Biology

Tuning of granulopoietic signaling by de novo designed agonists

T. Ullrich, C. Pollmann, M. Ritter, J. Haaf, N. Aghaallaei, I. Tesakov, M. El-Riz, K. Maksymenko, V. Hatskovska, S. Kandabarau, M. Klimiankou, C. Lengerke, K. Welte, B. Hernandez Alvarez, P. Müller, , M. ElGamacy

This paper designs and characterizes agonists that tune G-CSFR activity to bias granulopoiesis over proliferation, showing improved stability and selectivity compared to native G-CSF.

bioRxiv · Nov 25, 2023 · PreprintBioengineering

GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers

G. Bianco, M. Coto Llerena, J. Gallon, S. Taha-Mehlitz, V. Kancherla, M. Konantz, S. Srivatsa, H. Montazeri, F. Panebianco, M. De Menna, V. Paradiso, C. Ercan, A. Dahmani, E. Montaudon, N. Beerenwinkel, , S. Piscuoglio

This study identifies GATA3 and MDM2 as synthetic lethal in ER-positive breast cancers, showing MDM2 inhibition can target GATA3-deficient tumors via the PI3K/Akt/mTOR pathway.

bioRxiv · May 18, 2020Cancer Biology